AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34525247
Drug: Pre‐emptive 800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐emptive 800mg of intravenous ibuprofen plus 1000mg of intravenous paracetamol (Group IP)
Trial: 34525247
Drug: Only 1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only 1000mg of intravenous paracetamol (Group P)
Trial: 33242754
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 mg, days 1–4)
Trial: 32558305
Drug: topical nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical nepafenac (1 mg/ml) 1 drop 3 times per day for 3 days before surgery
Trial: 32558305
Drug: not receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: not receiving topical nepafenac (control group)
Trial: 35697571
Drug: Single booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single booster dose of 4CMenB in the infant + preschool group
Trial: 35697571
Drug: Single booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single booster dose of 4CMenB in the infant group
Trial: 35697571
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 4CMenB in naïve age-matched controls (adolescent 2 group)
Trial: 32445881
Drug: Monotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy group (IFN-α2b inhalation for 10–14 days)
Trial: 35483677
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 μg/kg
Trial: 33541815
Drug: 2% Olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Olive Leaf Extract (OLE) cream
Trial: 34967353
Drug: nano-modified Runji
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nano-modified Runji ointment
Trial: 35668682
Drug: Vehicle formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle formulation
Trial: 36117205
Drug: Dietary Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary Insulin Load (DIL) highest quartile
Trial: 36117205
Drug: Dietary Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary Insulin Load (DIL) highest quartile, adjusted for confounders
Trial: 36117205
Drug: Dietary Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary Insulin Load (DIL) highest quartile, further adjusted for BMI
Trial: 36117205
Drug: Dietary Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary Insulin Index (DII)
Trial: 36117205
Drug: Dietary Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary Insulin Load (DIL)
Trial: 32563846
Drug: Goal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal of opioid abstinence at treatment entry
Trial: 33455926
Drug: Iron isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron isomaltoside (IIM) 20 mg/kg
Trial: 35989346
Drug: Diltiazem 30
RxNorm normalized name: diltiazem 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 30 mg every 12 hours
Trial: 34125135
Drug: Brief cessation
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief cessation advice, a 1-week free sample of nicotine replacement therapy (NRT), and active referral to a community-based smoking cessation service.
Trial: 36279236
Drug: Neodolpasse (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neodolpasse (30 mg Orphenadrine and 75 mg Diclofenac)
Trial: 36279236
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with Morphine
Trial: 36279236
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with Morphine
Trial: 32727835
Drug: Ocrelizumab (OCR)
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab (OCR) 600 mg
Trial: 32727835
Drug: Control (interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (interferon beta or no disease-modifying therapy)
Trial: 34894702
Drug: Periarticular infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periarticular infiltration (PAI) with 100 mL cocktail solution (ropivacaine 20 mL, ketorolac 2 mL, epinephrine 1 mL mixed with normal saline)
Trial: 34894702
Drug: Pericapsular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pericapsular nerve group (PENG) block with 30 mL of 0.5% ropivacaine
Trial: 34118411
Drug: Continuous processing
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous processing of milled drug‐loaded electrospun materials to tablet form
Trial: 35938130
Drug: Mg +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg + B vitamins + green tea + rhodiola
Trial: 33896388
Drug: Mg +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg + B vitamins + rhodiola
Trial: 33896388
Drug: Mg +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg + B vitamins + green tea
Trial: 32174625
Drug: Customized oral
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized oral health educational video (Group A)
Trial: 32419038
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy strategies
Trial: 35293844
Drug: Select exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Select exercise modalities (e.g. treadmill exercise)
Trial: 34349379
Drug: Fentanyl patch
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl patch 25 μg·h‐1
Trial: 34349379
Drug: Buprenorphine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine patch 10 μg·h‐1
Trial: 34349379
Drug: Buprenorphine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine patch 20 μg·h‐1
Trial: 32028395
Drug: Conventional periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional periodontal treatment
Trial: 35179742
Drug: Independent predictors
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent predictors of NRF: age ≥ 65 years (OR: 2.473, p < 0.01), heart rate ≥ 89 bpm (OR: 1.622, p < 0.05), Killip class ≥ II (OR: 1.914, p < 0.01), total ischemic time ≥ 268 min (OR: 2.652, p < 0.01), thrombus burden G≥4 (OR: 8.351, p < 0.01)
Trial: 34009291
Drug: Perioperative systemic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative systemic therapy (CAPOX, FOLFOX, or FOLFIRI)
Trial: 36001429
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration (intravenous clamping procedure to achieve a breath alcohol concentration of 0.05% maintained over 3 hours)
Trial: 36001429
Drug: Self-administered alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered alcohol (intravenous)
Trial: 34463420
Drug: Dulaglutide 3.0
RxNorm normalized name: Dulaglutide 3.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [Trulicity]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 3.0 mg and 4.5 mg
Trial: 37097308
Drug: Telerehabilitation exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telerehabilitation exercise program (clinical Pilates-based exercises via YouTube, performed twice daily for 8 weeks)
Trial: 37264734
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg once daily
Trial: 35373340
Drug: Subgingival air-polishing
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival air-polishing therapy with erythritol powder (EPAP) as adjunct to conventional subgingival instrumentation
Trial: 34672254
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of terazosin hydrochloride (2 mg)
Trial: 34672254
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of terazosin hydrochloride (2 mg)
Trial: 34069308
Drug: Meal kit
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal kit provision (6 weekly kits, 3 meals per kit)
Trial: 33226524
Drug: darolutamide 600
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: darolutamide 600 mg twice daily
Trial: 36243580
Drug: HYR-PB21 300
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HYR-PB21 300 mg
Trial: 36243580
Drug: HYR-PB21 150
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HYR-PB21 150 mg
Trial: 36243580
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl 75 mg
Trial: 33822406
Drug: CT‐P17 AI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT‐P17 AI (40 mg/0.4 mL)
Trial: 33822406
Drug: CT‐P17 PFS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT‐P17 PFS (40 mg/0.4 mL)
Trial: 33730255
Drug: Received treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received treatment for HCV
Trial: 33524293
Drug: Rifaximin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (600 mg twice daily)
Trial: 33136048
Drug: Mandibular overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdentures retained by implants with 2 Locator attachments
Trial: 33262577
Drug: Escitalopram oxalate
RxNorm normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram oxalate 20 mg tablets (generic)
Trial: 34031262
Drug: Tight-Step-Up (TSU)
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tight-Step-Up (TSU) (MTX without oral GCs)
Trial: 34031262
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of total NSAID and analgesic use
Trial: 34031262
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of chronic NSAID and analgesic use
Trial: 34031262
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of daily chronic NSAID use
Trial: 33026143
Drug: efpeglenatide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efpeglenatide (4 mg or 6 mg)
Trial: 33189178
Drug: Selinexor (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (100 mg once per week), bortezomib (1.3 mg/m2 once per week), and dexamethasone (20 mg twice per week)
Trial: 33189178
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m2 twice per week for the first 24 weeks and once per week thereafter) and dexamethasone (20 mg four times per week for the first 24 weeks and twice per week thereafter)
Trial: 38320511
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg twice daily)
Trial: 33338442
Drug: sequential FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential FOLFIRINOX
Trial: 33964325
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months of androgen deprivation therapy (ADT) plus high-dose radiotherapy (HRT)
Trial: 32294560
Drug: Lidocaine 7%
RxNorm normalized name: LIDOCAINE 7%/TETRACAINE 7% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 7% and Tetracaine 7% self-occlusive cream (LT-C), applied 1 hour before MAL-cPDT session.
Trial: 32294560
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream (control group).
Trial: 32294560
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of LT-C vs Vehicle cream.
Trial: 36371994
Drug: Trastuzumab-plus-chemotherapy group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab-plus-chemotherapy group (n = 36)
Trial: 36371994
Drug: Trastuzumab-monotherapy group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab-monotherapy group (n = 52)
Trial: 32183768
Drug: Eurythmy therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurythmy therapy (EYT) and Tai Chi
Trial: 38522443
Drug: Low-flow oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow oxygen therapy
Trial: 33245905
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor (ACEI) therapy
Trial: 33245905
Drug: Target dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target dosing of beta-blocker and ACEI therapy
Trial: 32819445
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (IV-TXA 15 mg/kg + local TXA 2 g)
Trial: 32819445
Drug: IV group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV group (IV-TXA 15 mg/kg)
Trial: 32819445
Drug: Topical group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical group (local TXA 2 g)
Trial: 32819445
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (100 mL IV)
Trial: 33048875
Drug: Combination prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination prevention intervention with universal ART (Arm A)
Trial: 32773450
Drug: Myostatin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myostatin inhibitors
Trial: 35347399
Drug: Balneological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneological treatment (peloidotherapy + hydrotherapy)
Trial: 35347399
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (balneological treatment and control)
Trial: 33971731
Drug: Services from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Services from a similar team that includes a nurse care coordinator for medication management support and medical care
Trial: 35629233
Drug: Ramosetron (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron (0.3 mg after anesthetic induction)
Trial: 32335950
Drug: 0.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 mg oestradiol benzoate (0EB group; n=12)
Trial: 32335950
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg oestradiol benzoate (0.5EB group; n=12)
Trial: 32335950
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg oestradiol benzoate (1.0EB group; n=12)
Trial: 32828837
Drug: Trials with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trials with non-significant difference between treatments for primary outcome
Trial: 34530594
Drug: Rivaroxaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (2.5 mg twice a day) plus Aspirin (100 mg once a day)
Trial: 32770831
Drug: CBDV (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBDV (400 mg/day)
Trial: 33420287
Drug: Reduced-dose posttransplant
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose posttransplant cyclophosphamide (20 mg/kg for MSD-PTCy cohort, 25 mg/kg for haplo-PTCy cohort) on days +3, +4 combined with cotransplantation of peripheral blood stem cells (PBSCs) and human umbilical cord-derived mesenchymal stem cells (UC-MSCs)
Trial: 33420287
Drug: Reduced-dose posttransplant
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose posttransplant cyclophosphamide (20 mg/kg for MSD-PTCy cohort, 25 mg/kg for haplo-PTCy cohort) on days +3, +4 combined with cotransplantation of PBSCs and UC-MSCs
Trial: 36444391
Drug: CHECC‐uP intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHECC‐uP intervention (cervical cancer brochure plus 30-60 min health literacy-focused education followed by monthly phone counselling and navigation assistance for 6 months)
Trial: 34029521
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU 4 times per day for 8 weeks)
Trial: 36058058
Drug: 1.5 kcal/ml
RxNorm normalized name: lactose-reduced food 0.05 gram-1.5 kcal/mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 kcal/ml enteral formula
Trial: 36058058
Drug: 1.0 kcal/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 kcal/ml enteral formula
Trial: 34154344
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) combined with transcranial direct current stimulation (tDCS)
Trial: 32020044
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy with lenalidomide (20 mg/day for days 1-21)
Trial: 32020044
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy without lenalidomide
Trial: 32020044
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy with lenalidomide
Trial: 33596722
Drug: Cyproheptadine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (8 mg, competitive 5-HT2 antagonist)
Trial: 35422427
Drug: TD139 (0.3-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD139 (0.3-10 mg once daily for 14 days)
Trial: 35422427
Drug: TD139 (0.15-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD139 (0.15-50 mg single doses)
Trial: 34599040
Drug: Octreotide acetate
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide acetate (low, medium, and high doses)
Trial: 32114729
Drug: rhGM‐CSF gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM‐CSF gel (10 mg per square centimeter, dressing change every 24 hours until complete healing)
Trial: 32114729
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (aloe vera gel, same treatment protocol)
Trial: 34059974
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied before implant bed preparation and after suturing (808-nm GaAlA laser, 80 seconds; 11J/cm2)
Trial: 33139757
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 g of maltodextrin)
Trial: 33454232
Drug: Lavender essential
RxNorm normalized name: Nature's Truth Lavender Essential Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender essential oil inhalation (3 drops of 1.5% for 30 nights)
Trial: 33454232
Drug: Chamomile essential
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile essential oil inhalation (3 drops of 1.5% for 30 nights)
Trial: 33454232
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (inhalation of distilled water for 30 nights)
Trial: 36414783
Drug: One-shot cognitive
RxNorm normalized name: ChoreMate One-Shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-shot cognitive behavioral therapy for insomnia (CBT-I)
Trial: 32960536
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (AT; prophylactic antibiotics and steroids)
Trial: 32960536
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (AT-free group)
Trial: 32960536
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (AT)
Trial: 36281094
Drug: Preoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous fluid loading with Ringer's lactate solution
Trial: 33638801
Drug: Evolocumab (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (140 mg subcutaneously injected once before revascularization + 14 days after the first dose)